Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also make tumor cells more sensitive to radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This randomized phase I/II trial is studying the best dose of dasatinib and to see how well it works compared with a placebo when given together with radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma multiforme.

Further Study Information

OBJECTIVES:

• To establish a maximum-tolerated dose of dasatinib combined with radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme. (Phase I) (Phase I study closed to patient accrual on April 29, 2011 and has been completed)

• To determine the efficacy of dasatinib in combination with radiotherapy and concomitant adjuvant temozolomide, and compare it with the standard of care approach, consisting of radiotherapy and temozolomide, followed by adjuvant temozolomide in these patients. (Phase II) (Phase II study opened to patient accrualon August 5, 2011)

• To determine the relationship between tumor biomarkers and clinical outcome of patients treated with the dasatinib/radiotherapy/temozolomide combination. (Phase II)

• To evaluate potential mechanisms of therapy resistance in recurrent tumor samples obtained at the time of surgery for recurrent disease.

• To assess the impact of the addition of dasatinib to radiotherapy and temozolomide on the quality of life (QOL) of these patients, as assessed by FACT-Br, EORTC QLQ-C15-PAL, and EORTC QLQ-BN20. (Phase II)

• To compare the results of the two most commonly used QOL tools, FACT-Br and EORTC QLQ C15-PAL plus BN20 and validate the use of EORTC QLQ-C15-PAL plus BN20 in these patients.(Phase II)

OUTLINE: This is a multicenter, phase I dose-escalation study of dasatinib (Phase I study closed to patient accrual on April 29, 2011 and has been completed) followed by a randomized phase II study (Phase II study opened to patient accrual on August 5, 2011).

• Phase I:

• Course 1: Patients receive oral dasatinib once daily and oral temozolomide once daily on days 1-42. Patients undergo external-beam radiotherapy (EBRT), including intensity-modulated radiotherapy, 5 days a week for 6 weeks.

• Courses 2-7: Beginning 28-42 days after course 1, patients receive oral dasatinib once daily on days 1-28 and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

• Phase II: Patients are stratified according to age (> 70 years vs ≤ 70 years). Patients are randomized to 1 of 2 treatment arms.

• Arm I:

• Course 1: Patients receive oral dasatinib once daily and oral temozolomide once daily on days 1-42. Patients undergo EBRT 5 days a week for 6 weeks.

• Courses 2-7: Beginning 28-42 days after course 1, patients receive oral dasatinib once daily on days 1-28 and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

• Arm II:

• Course 1: Patients receive oral placebo once daily on days 1-42 and temozolomide as in arm I. Patients also undergo EBRT as in arm I.

• Courses 2-7: Beginning 28-42 days after course 1, patients receive oral placebo once daily on days 1-28 and temozolomide as in arm I. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Tissue samples are collected for correlative studies.

Quality of life is assessed periodically using the FACT-Br, EORTC QLQ-C15-PAL v.1, and EORTC BN-20 questionnaires.

After completion of study therapy, patients are followed up every 6 months for 5 years.

Eligibility Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed glioblastoma multiforme (GBM)

• Grade 4 astrocytoma

• No grade 4 oligoastrocytoma or GBM with oligodendroglial features

• Newly diagnosed disease

• Measurable or evaluable disease by gadolinium MRI or contrast CT scan

• Patients who have had a gross total resection are eligible on the basis of evaluable disease

• No pleural or pericardial effusion of any grade

• No prior surgery for CNS neoplasms other than surgery related to the current GBM diagnosis

• If Gliadel wafers are placed at time of primary resection this would be considered prior therapy and patient would be ineligible

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Absolute neutrophil count (ANC) ≥ 1,500/mm³

• Platelet count ≥ 100,000/mm³

• Hemoglobin > 9.0 g/dL

• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

• AST ≤ 2.5 times ULN

• Creatinine ≤ 1.5 times ULN

• INR ≤ 1.5

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for ≥ 12 weeks after completion of study treatment

• No immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be HIV positive and currently receiving antiretroviral therapy

• Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial

• No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

• No history of any of the following conditions:

• Congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

• Congenital long QT syndrome

• Clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)

• Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)

• Hypokalemia or hypomagnesemia

• Patients may not have any clinically significant cardiovascular disease including the following:

• Myocardial infarction or ventricular tachyarrhythmia within 6 months

• Ejection fraction less than institutional normal

• Major conduction abnormality (unless a cardiac pacemaker is present)

• New York Heart Association classification ≥ class II congestive heart failure

• Patients with any cardiopulmonary symptoms of unknown cause (e.g., shortness of breath, chest pain, etc.) should be evaluated by a baseline echocardiogram with or without stress test as needed in addition to electrocardiogram (ECG) to rule out QTc prolongation

• Patients with underlying cardiopulmonary dysfunction should be excluded from the study

• No comorbid systemic illnesses or other severe concurrent disease that, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens including, but not limited to, any of the following:

• History of bleeding diathesis

• Concurrent chronic systemic anticoagulation therapy that can not be discontinued (i.e., antiplatelet agents or aspirin)

• Concurrent t chronic nonsteroidal anti-inflammatory drugs (NSAIDs) that cannot be discontinued

• No other active malignancy ≤ 5 years prior to registration

• Exceptions: Non-melanotic skin cancer or carcinoma-in-situ of the cervix

• If there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer

• No severe allergy to sulfa medications and dapsone

• Able to tolerate either intravenous or inhaled dapsone

• Able to take oral medication

• Willingness to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study treatment

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• See Patient Characteristics

• At least 5 days since prior and no concurrent St. John wort

• No prior radiotherapy or chemotherapy for any CNS neoplasm (hormones, vitamins, and growth factors are not considered chemotherapy for the purposes of this study)

• At least 7 days, but < 42 days, since prior stereotactic biopsy

• At least 14 days, but < 42 days, since prior open craniotomy

• Willing to forego other cytotoxic and non-cytotoxic drug therapy against the tumor while being treated with dasatinib and temozolomide

• No other concurrent investigational agent considered as treatment for the primary neoplasm

• Must not be currently taking any of the following medications:

• Enzyme-inducing anticonvulsants (EIACs)

• To be eligible, patient must be switched to non-EIAC medications ≥ 7 days prior to registration

• Potent inhibitors of CYP3A4 that cannot be discontinued

• Medications that may possibly prolong QT interval and produce a QTc that is ≥ 60 msec or a QTcF that is ≥ 450 msec

• H2 blockers or proton pump inhibitors (PPIs), such as famotidine (Pepcid) and omeprazole (Prilosec) respectively, that cannot be discontinued or switched to locally acting agents, such as Maalox, Mylanta, or TUMS

• No concurrent treatment immunosuppressive agent, except corticosteroids

• No concurrent other anticancer agents

• No concurrent prophylactic leukocyte growth factors (e.g., filgrastim [G-CSF] and sargramostim [GM-CSF])

• No concurrent live vaccines

• No concurrent therapeutic anticoagulation with warfarin

• No concurrent ibuprofen or other nonsteroidal anti-inflammatory drugs (NSAIDs)

Trial Contact Information

Trial Lead Organizations/Sponsors

North Central Cancer Treatment Group

Nadia N. Laack

Study Chair

U.S.A.
Connecticut
	Hartford
	Helen and Harry Gray Cancer Center at Hartford Hospital
		Alexandra F Flowers	Ph: 860-545-5363
Georgia
	Columbus
	John B. Amos Cancer Center
		Andrew W. Pippas	Ph: 706-660-6404
Illinois
	Bloomington
	St. Joseph Medical Center
		John W. Kugler	Ph: 800-793-2262
	Bloomington%
	Illinois CancerCare - Bloomington
		John W. Kugler	Ph: 800-793-2262
	Canton
	Illinois CancerCare - Canton
		John W. Kugler	Ph: 800-793-2262
	Carthage
	Illinois CancerCare - Carthage
		John W. Kugler	Ph: 800-793-2262
	Chicago
	Creticos Cancer Center at Advocate Illinois Masonic Medical Center
		Deepti A. Singh	Ph: 773-296-5360
	Resurrection Medical Center
		Christopher G. Rose	Ph: 773-792-5116
	Eureka
	Eureka Community Hospital
		John W. Kugler	Ph: 800-793-2262
	Illinois CancerCare - Eureka
		John W. Kugler	Ph: 800-793-2262
	Havana
	Illinois CancerCare - Havana
		John W. Kugler	Ph: 800-793-2262
	Kewanee
	Illinois CancerCare - Kewanee Clinic
		John W. Kugler	Ph: 800-793-2262
	Macomb
	Illinois CancerCare - Macomb
		John W. Kugler	Ph: 800-793-2262
	Monmouth
	Illinois CancerCare - Monmouth
		John W. Kugler	Ph: 800-793-2262
	OSF Holy Family Medical Center
		John W. Kugler	Ph: 800-793-2262
	Normal
	BroMenn Regional Medical Center
		John W. Kugler	Ph: 800-793-2262
	Community Cancer Center
		John W. Kugler	Ph: 800-793-2262
	Illinois CancerCare - Community Cancer Center
		John W. Kugler	Ph: 800-793-2262
	Ottawa
	Community Hospital of Ottawa
		John W. Kugler	Ph: 800-793-2262
	Illinois CancerCare - Ottawa
		John W. Kugler	Ph: 800-793-2262
	Pekin
	Cancer Treatment Center at Pekin Hospital
		John W. Kugler	Ph: 800-793-2262
	Illinois CancerCare - Pekin
		John W. Kugler	Ph: 800-793-2262
	Peoria
	CCOP - Illinois Oncology Research Association
		John W. Kugler	Ph: 800-793-2262
	Illinois CancerCare - Peoria
		John W. Kugler	Ph: 800-793-2262
	Methodist Medical Center of Illinois
		John W. Kugler	Ph: 800-793-2262
	OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC
		Nguyet A Le-Lindqwister	Ph: 800-793-2262
	OSF St. Francis Medical Center
		John W. Kugler	Ph: 800-793-2262
	Proctor Hospital
		John W. Kugler	Ph: 800-793-2262
	Peru
	Illinois CancerCare - Princeton
		John W. Kugler	Ph: 800-793-2262
	Illinois Valley Community Hospital
		John W. Kugler	Ph: 800-793-2262
	Princeton
	Illinois CancerCare - Princeton
		John W. Kugler	Ph: 800-793-2262
	Spring Valley
	Illinois CancerCare - Spring Valley
		John W. Kugler	Ph: 800-793-2262
	Valley Cancer Center
		Nguyet A Le-Lindqwister	Ph: 800-793-2262
	Urbana
	Carle Cancer Center at Carle Foundation Hospital
		Kalika P. Sarma	Ph: 800-446-5532
Indiana
	Elkhart
	Elkhart Clinic, LLC
		Robin Zon	Ph: 574-234-5123
	Elkhart General Hospital
		Robin Zon	Ph: 574-234-5123
	Michiana Hematology-Oncology, PC - Elkhart
		Robin Zon	Ph: 574-234-5123
	Indianapolis
	St. Francis Hospital Cancer Care Services
		Howard M. Gross	Ph: 765-983-3000
	Kokomo
	Community Cancer Care at Howard Regional Health System
		Robin Zon	Ph: 574-234-5123
	La Porte
	Center for Cancer Therapy at LaPorte Hospital and Health Services
		Robin Zon	Ph: 574-234-5123
	Mishawaka
	Michiana Hematology-Oncology, PC - Mishawaka
		Robin Zon	Ph: 574-234-5123
	Saint Joseph's Medical Center
		Robin Zon	Ph: 574-234-5123
	Plymouth
	Michiana Hematology Oncology PC - Plymouth
		Robin Zon	Ph: 574-234-5123
	Richmond
	Reid Hospital & Health Care Services
		Howard M. Gross	Ph: 317-783-8918
	South Bend
	CCOP - Northern Indiana CR Consortium
		Robin Zon	Ph: 574-234-5123
	Memorial Hospital of South Bend
		Robin Zon	Ph: 574-234-5123
	Michiana Hematology-Oncology, PC - South Bend
		Robin Zon	Ph: 574-234-5123
	Westville
	Michiana Hematology Oncology-PC Westville
		Robin Zon	Ph: 574-234-5123
Iowa
	Cedar Rapids
	Cedar Rapids Oncology Associates
		Deborah W Wilbur	Ph: 319-363-2690
		Deborah W Wilbur	Ph: 319-363-2690
	Mercy Regional Cancer Center at Mercy Medical Center
		Deborah W Wilbur	Ph: 319-363-2690
	Clive
	Medical Oncology and Hematology Associates-West Des Moines
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
	Mercy Cancer Center - West Lakes
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
	Des Moines
	CCOP - Iowa Oncology Research Association
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
	John Stoddard Cancer Center at Iowa Lutheran Hospital
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
	John Stoddard Cancer Center at Iowa Methodist Medical Center
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
	Medical Oncology and Hematology Associates at John Stoddard Cancer Center
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
	Medical Oncology and Hematology Associates at Mercy Cancer Center
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
	Mercy Cancer Center at Mercy Medical Center - Des Moines
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
	Sioux City
	Mercy Medical Center - Sioux City
		Donald Bruce Wender	Ph: 712-252-0088
	Siouxland Hematology-Oncology Associates, LLP
		Donald Bruce Wender	Ph: 712-252-0088
	St. Luke's Regional Medical Center
		Donald Bruce Wender	Ph: 712-252-0088
	West Des Moines
	Methodist West Hospital
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
Kansas
	Chanute
	Cancer Center of Kansas, PA - Chanute
		Shaker R. Dakhil	Ph: 316-262-4467
	Dodge City
	Cancer Center of Kansas, PA - Dodge City
		Shaker R. Dakhil	Ph: 316-262-4467
	El Dorado
	Cancer Center of Kansas, PA - El Dorado
		Shaker R. Dakhil	Ph: 316-262-4467
	Fort Scott
	Cancer Center of Kansas - Fort Scott
		Shaker R. Dakhil	Ph: 316-262-4467
	Independence
	Cancer Center of Kansas-Independence
		Shaker R. Dakhil	Ph: 316-262-4467
	Kingman
	Cancer Center of Kansas, PA - Kingman
		Shaker R. Dakhil	Ph: 316-262-4467
	Lawrence
	Lawrence Memorial Hospital
		Shaker R. Dakhil	Ph: 316-262-4467
	Liberal
	Cancer Center of Kansas, PA - Liberal
		Shaker R. Dakhil	Ph: 316-262-4467
	Newton
	Cancer Center of Kansas, PA - Newton
		Shaker R. Dakhil	Ph: 316-262-4467
	Parsons
	Cancer Center of Kansas, PA - Parsons
		Shaker R. Dakhil	Ph: 316-262-4467
	Pratt
	Cancer Center of Kansas, PA - Pratt
		Shaker R. Dakhil	Ph: 316-262-4467
	Salina
	Cancer Center of Kansas, PA - Salina
		Shaker R. Dakhil	Ph: 316-262-4467
	Wellington
	Cancer Center of Kansas, PA - Wellington
		Shaker R. Dakhil	Ph: 316-262-4467
	Wichita
	Associates in Women's Health, PA - North Hillside
		Shaker R. Dakhil	Ph: 316-262-4467
	Cancer Center of Kansas, PA - Medical Arts Tower
		Shaker R. Dakhil	Ph: 316-262-4467
	Cancer Center of Kansas, PA - Wichita
		Shaker R. Dakhil	Ph: 316-262-4467
	CCOP - Wichita
		Shaker R. Dakhil	Ph: 316-262-4467
	Via Christi Cancer Center at Via Christi Regional Medical Center
		Shaker R. Dakhil	Ph: 316-262-4467
	Wesley Medical Center
		Shaker R. Dakhil	Ph: 316-262-4467
	Winfield
	Cancer Center of Kansas, PA - Winfield
		Shaker R. Dakhil	Ph: 316-262-4467
Michigan
	Adrian
	Hickman Cancer Center at Bixby Medical Center
		Rex B Mowat	Ph: 517-265-0116
		Rex B Mowat	Ph: 517-265-0116
	Monroe
	Community Cancer Center of Monroe
		Rex B Mowat	Ph: 517-265-0116
	Mercy Memorial Hospital - Monroe
		Rex B Mowat	Ph: 517-265-0116
	Saint Joseph
	Lakeside Cancer Specialists, PLLC
		Robin Zon	Ph: 574-234-5123
	St. Joseph
	Lakeland Regional Cancer Care Center - St. Joseph
		Robin Zon	Ph: 574-234-5123
Minnesota
	Bemidji
	MeritCare Bemidji
		Preston D. Steen	Ph: 701-234-6161
	Burnsville
	Fairview Ridges Hospital
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Coon Rapids
	Mercy and Unity Cancer Center at Mercy Hospital
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Duluth
	CCOP - Duluth
		Bret E Friday	Ph: 888-203-7267
	Essentia Health - Duluth Clinic
		Bret E Friday	Ph: 888-203-7267
	Miller - Dwan Medical Center
		Bret E Friday	Ph: 888-203-7267
	Edina
	Fairview Southdale Hospital
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Fridley
	Mercy and Unity Cancer Center at Unity Hospital
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Hutchinson
	Hutchinson Area Health Care
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Maplewood
	HealthEast Cancer Care at St. John's Hospital
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Minnesota Oncology - Maplewood
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Minneapolis
	Hennepin County Medical Center - Minneapolis
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Robbinsdale
	Humphrey Cancer Center at North Memorial Outpatient Center
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Rochester
	Mayo Clinic Cancer Center
		Nadia N Laack	Ph: 507-538-7623
	North Central Cancer Treatment Group
		Nadia N Laack	Ph: 507-284-3559
			Email: laack.nadia@mayo.edu
	Saint Cloud
	CentraCare Clinic - Women and Children
		Donald J Jurgens	Ph: 877-229-4907
			Email: coborncancercenter@centracare.com
	Coborn Cancer Center
		Donald J Jurgens	Ph: 877-229-4907
			Email: coborncancercenter@centracare.com
	Saint Louis Park
	CCOP - Metro-Minnesota
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Park Nicollet Cancer Center
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Saint Paul
	Regions Hospital Cancer Care Center
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	United Hospital
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Shakopee
	St. Francis Cancer Center at St. Francis Medical Center
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Stillwater
	Lakeview Hospital
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Waconia
	Ridgeview Medical Center
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Willmar
	Willmar Cancer Center at Rice Memorial Hospital
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Woodbury
	Minnesota Oncology - Woodbury
		Daniel M Anderson	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
Missouri
	Saint Louis
	Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
		David D Tran	Ph: 800-600-3606
			Email: info@siteman.wustl.edu
Montana
	Billings
	Billings Clinic Cancer Center - 801 N 29th Street
		Benjamin Thomas Marchello	Ph: 800-648-6274
	CCOP - Montana Cancer Consortium
		Benjamin Thomas Marchello	Ph: 800-648-6274
	Hematology-Oncology Centers of the Northern Rockies - Billings
		Benjamin Thomas Marchello	Ph: 800-648-6274
	St. Vincent Healthcare Cancer Care Services
		Benjamin Thomas Marchello	Ph: 800-648-6274
	Bozeman
	Bozeman Deaconess Cancer Center
		Benjamin Thomas Marchello	Ph: 800-648-6274
	Butte
	St. James Healthcare Cancer Care
		Benjamin Thomas Marchello	Ph: 800-648-6274
	Great Falls
	Benefis Sletten Cancer Institute
		Benjamin Thomas Marchello	Ph: 800-648-6274
	Helena
	St. Peter's Hospital
		Benjamin Thomas Marchello	Ph: 800-648-6274
	Kalispell
	Kalispell Regional Medical Center
		Benjamin Thomas Marchello	Ph: 800-648-6274
	Missoula
	Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
		Benjamin Thomas Marchello	Ph: 800-648-6274
	Montana Cancer Specialists at Montana Cancer Center
		Benjamin Thomas Marchello	Ph: 800-648-6274
New Hampshire
	Concord
	New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
		Douglas Jay Weckstein	Ph: 603-224-2556
	Hooksett
	New Hampshire Oncology - Hematology, PA - Hooksett
		Douglas Jay Weckstein	Ph: 603-224-2556
	Laconia
	Lakes Region General Hospital
		Douglas Jay Weckstein	Ph: 603-224-2556
New Mexico
	Albuquerque
	University of New Mexico Cancer Center
		Fa-Chyi Lee	Ph: 505-727-8000
New York
	East Syracuse
	CCOP - Hematology-Oncology Associates of Central New York
		Jeffrey J. Kirshner	Ph: 315-472-7504
North Carolina
	Asheville
	Mission Hospitals - Memorial Campus
		Christopher H Chay	Ph: 828-213-4150
	Goldsboro
	Wayne Memorial Hospital, Incorporated
		James N. Atkins	Ph: 919-580-0000
North Dakota
	Bismarck
	Medcenter One Hospital Cancer Care Center
		John T Reynolds	Ph: 701-323-5760
			Email: tfischer@mohs.org
	Mid Dakota Clinic, PC
		John T Reynolds	Ph: 701-323-5760
			Email: tfischer@mohs.org
	St. Alexius Medical Center Cancer Center
		John T Reynolds	Ph: 701-323-5760
			Email: tfischer@mohs.org
	Fargo
	Sanford Clinic North-Fargo
		Preston D. Steen	Ph: 701-234-6161
	Grand Forks
	Altru Cancer Center at Altru Hospital
		Grant R Seeger	Ph: 701-780-6520
Ohio
	Bowling Green
	Wood County Oncology Center
		Rex B Mowat	Ph: 517-265-0116
	Chillicothe
	Adena Regional Medical Center
		J. Philip Kuebler	Ph: 614-566-3275
	Cincinnati
	University of Cincinnati
		Howard M. Gross	Ph: 317-783-8918
	Columbus
	CCOP - Columbus
		J. Philip Kuebler	Ph: 614-566-3275
	Doctors Hospital at Ohio Health
		J. Philip Kuebler	Ph: 614-566-3275
	Grant Medical Center Cancer Care
		J. Philip Kuebler	Ph: 614-566-3275
	Mount Carmel Health - West Hospital
		J. Philip Kuebler	Ph: 614-566-3275
	Riverside Methodist Hospital Cancer Care
		J. Philip Kuebler	Ph: 614-566-3275
	Dayton
	CCOP - Dayton
		Howard M. Gross	Ph: 317-783-8918
	David L. Rike Cancer Center at Miami Valley Hospital
		Howard M. Gross	Ph: 317-783-8918
	Good Samaritan Hospital
		Howard M. Gross	Ph: 317-783-8918
	Grandview Hospital
		Howard M. Gross	Ph: 317-783-8918
	Samaritan North Cancer Care Center
		Howard M. Gross	Ph: 317-783-8918
	Delaware
	Grady Memorial Hospital
		J. Philip Kuebler	Ph: 614-566-3275
	Elyria
	Hematology Oncology Center
		Rex B Mowat	Ph: 517-265-0116
	Mercy Cancer Center - Elyria
		Rex B Mowat	Ph: 517-265-0116
	Findlay
	Blanchard Valley Regional Cancer Center
		Howard M. Gross	Ph: 317-783-8918
	Franklin
	Atrium Medical Center
		Howard M. Gross	Ph: 317-783-8918
	Greenville
	Wayne Hospital
		Howard M. Gross	Ph: 317-783-8918
	Kettering
	Charles F. Kettering Memorial Hospital
		Howard M. Gross	Ph: 317-783-8918
	Lancaster
	Fairfield Medical Center
		J. Philip Kuebler	Ph: 614-566-3275
	Lima
	Lima Memorial Hospital
		Rex B Mowat	Ph: 517-265-0116
	Marietta
	Strecker Cancer Center at Marietta Memorial Hospital
		J. Philip Kuebler	Ph: 614-566-3275
	Maumee
	Northwest Ohio Oncology Center
		Rex B Mowat	Ph: 517-265-0116
		Rex B Mowat	Ph: 517-265-0116
	Mount Vernon
	Knox Community Hospital
		J. Philip Kuebler	Ph: 614-566-3275
	Newark
	Licking Memorial Cancer Care Program at Licking Memorial Hospital
		J. Philip Kuebler	Ph: 614-566-3275
	Oregon
	St. Charles Mercy Hospital
		Rex B Mowat	Ph: 517-265-0116
	Toledo Clinic - Oregon
		Rex B Mowat	Ph: 517-265-0116
	Portsmouth
	Southern Ohio Medical Center Cancer Center
		J. Philip Kuebler	Ph: 614-566-3275
	Springfield
	Community Hospital of Springfield and Clark County
		J. Philip Kuebler	Ph: 614-566-3275
	Sylvania
	Flower Hospital Cancer Center
		Rex B Mowat	Ph: 517-265-0116
	Tiffin
	Mercy Hospital of Tiffin
		Rex B Mowat	Ph: 517-265-0116
	Toledo
	St. Anne Mercy Hospital
		Rex B Mowat	Ph: 517-265-0116
	St. Vincent Mercy Medical Center
		Rex B Mowat	Ph: 517-265-0116
	Toledo Clinic, Incorporated - Main Clinic
		Rex B Mowat	Ph: 517-265-0116
	Toledo Hospital
		Rex B Mowat	Ph: 517-265-0116
	University of Toledo Medical Center
		Rex B Mowat	Ph: 517-265-0116
	Troy
	UVMC Cancer Care Center at Upper Valley Medical Center
		Howard M. Gross	Ph: 317-783-8918
	Wauseon
	Fulton County Health Center
		Rex B Mowat	Ph: 517-265-0116
	West Chester
	University Pointe
		Howard M. Gross	Ph: 317-783-8918
	Westerville
	Mount Carmel St. Ann's Cancer Center
		J. Philip Kuebler	Ph: 614-566-3275
	Xenia
	Ruth G. McMillan Cancer Center at Greene Memorial Hospital
		Howard M. Gross	Ph: 317-783-8918
	Zanesville
	Genesis - Good Samaritan Hospital
		J. Philip Kuebler	Ph: 614-566-3275
Oklahoma
	Tulsa
	Natalie Warren Bryant Cancer Center at St. Francis Hospital
		Alan M Keller	Ph: 918-499-2000
Pennsylvania
	Allentown
	Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
		Suresh G. Nair	Ph: 610-402-2273
South Carolina
	Easley
	Cancer Centers of the Carolinas - Easley
		David L Grisell	Ph: 864-241-6251
	Greenville
	Cancer Centers of the Carolinas - Andrews
		David L Grisell	Ph: 864-241-6251
	Cancer Centers of the Carolinas - Faris Road
		David L Grisell	Ph: 864-241-6251
	Cancer Centers of the Carolinas - Grove Commons
		David L Grisell	Ph: 864-241-6251
	CCOP - Greenville
		David L Grisell	Ph: 864-241-6251
	Greenville Memorial Hospital
		David L Grisell	Ph: 864-241-6251
	Greer
	Cancer Centers of the Carolinas - Greer Medical Oncology
		David L Grisell	Ph: 864-241-6251
	Cancer Centers of the Carolinas - Greer Radiation Oncology
		David L Grisell	Ph: 864-241-6251
	Seneca
	Cancer Centers of the Carolinas - Seneca
		David L Grisell	Ph: 864-241-6251
	Spartanburg
	Cancer Centers of the Carolinas - Spartanburg
		David L Grisell	Ph: 864-241-6251
South Dakota
	Rapid City
	Rapid City Regional Hospital
		Mark T Schroeder	Ph: 605-716-3982
			Email: research@rcrh.org
	Sioux Falls
	Avera Cancer Institute
		Addison R Tolentino	Ph: 800-657-4377
			Email: Jan.Healy@avera.org
	Sanford Cancer Center at Sanford USD Medical Center
		Miroslaw A Mazurczak	Ph: 605-328-1367
		Miroslaw A Mazurczak	Ph: 605-328-1367
Virginia
	Fredericksburg
	Fredericksburg Oncology Inc
		Rex B Mowat	Ph: 517-265-0116
Wisconsin
	Eau Claire
	Center for Cancer Treatment & Prevention at Sacred Heart Hospital
		Benjamin E. Lawler	Ph: 715-389-4457
	Marshfield Clinic Cancer Care at Regional Cancer Center
		Benjamin E. Lawler	Ph: 715-389-4457
	Fond Du Lac
	Central Wisconsin Cancer Program at Agnesian HealthCare
		Timothy P Korytko	Ph: 800-494-2927
	La Crosse
	Gundersen Lutheran Center for Cancer and Blood
		Kurt Oettel	Ph: 608-775-2385
			Email: cancerctr@gundluth.org
	Marshfield
	Marshfield Clinic - Marshfield Center
		Benjamin E. Lawler	Ph: 715-389-4457
	Saint Joseph's Hospital
		Benjamin E. Lawler	Ph: 715-389-4457
	Minocqua
	Marshfield Clinic - Lakeland Center
		Benjamin E. Lawler	Ph: 715-389-4457
	Rhinelander
	Ministry Medical Group at Saint Mary's Hospital
		Benjamin E. Lawler	Ph: 715-389-4457
	Rice Lake
	Marshfield Clinic - Indianhead Center
		Benjamin E. Lawler	Ph: 715-389-4457
	Stevens Point
	Marshfield Clinic at Saint Michael's Hospital
		Benjamin E. Lawler	Ph: 715-389-4457
	Saint Michael's Hospital Cancer Center
		Benjamin E. Lawler	Ph: 715-389-4457
	Weston
	Marshfield Clinic - Weston Center
		Benjamin E. Lawler	Ph: 715-389-4457

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00869401
Information obtained from ClinicalTrials.gov on February 21, 2013

Back to Top